7 Review of guidance

7 Review of guidance

7.1.1 The guidance on this technology will be considered for review by the Guidance Executive in July 2013. The Appraisal Committee noted that the ICER was sensitive to reductions in the price of zoledronic acid, and was aware that zoledronic acid is due to come off patent in 2013 and that this may result in a reduction in the price of zoledronic acid because of the availability of cheaper generic versions. In that scenario, the cost-effective analysis that it based its decision on would need to be revised.

Andrew Dillon
Chief Executive
October 2012

  • National Institute for Health and Care Excellence (NICE)